Navigation Links
Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action

SWEDESBORO, N.J., Dec. 12 /PRNewswire/ -- Yesterday, the U.S. Court of Appeals for the District of Columbia Circuit vacated the Drug Enforcement Administration's (DEA) 2006 revocation of Wedgewood Pharmacy's registration to dispense controlled substances. Wedgewood has been challenging the DEA's decision since it first was issued.

The ruling consolidated two petitions: the company's appeal of the DEA's decision and the DEA's denial of Wedgewood's petition for reconsideration. The court explained that it does not set-aside Federal agency rulings "unless the interpretation is arbitrary, capricious, or manifestly contrary to the statute ... [and] if the agency ... entirely failed to consider an important aspect of the problem, offered an explanation for its decision that runs counter to the evidence before the agency, or is so implausible that it could not be ascribed to a difference in view or the product of agency expertise." The unanimous ruling, authored by Circuit Judge Karen LeCraft Henderson, noted "we cannot help but conclude that the DA's [DEA's Deputy Administrator] decision 'entirely failed to consider an important aspect of the problem,'" that is, "whether animal medicine operates differently from human medicine."

George J. Malmberg, R.Ph., F.A.C.A, F.A.C.V.P., the pharmacist president and CEO of Wedgewood Pharmacy, noted: "The Court made clear its concern that the practice of veterinary medicine differs from the practice of human medicine. We believe that the current standard of practice in our profession, which is to dispense controlled substances to veterinarians rather than to horse owners or stable personnel, is consistent with the law's intention to prevent the improper use of controlled substances. We look forward to having our registration restored by the DEA, though the timing of that will depend upon the agency's response to this ruling."

The DEA objected to Wedgewood's practice of preparing compounded controlled-substances and then delivering the medications to veterinarians and physicians instead of directly to their patients. DEA viewed these practices as "manufacturing" and "distributing" controlled substances as defined by the Controlled Substances Act. Under Wedgewood's then DEA-registration as a "practitioner," however, it was authorized only to "compound" and "dispense" controlled substances. Wedgewood argued that "dispensing" includes constructive delivery to an animal patient through a licensed veterinarian.

In vacating the revocation of Wedgewood's registration to dispense controlled substances, the court remanded the case to the DEA "for further proceedings consistent with this order," saying that the "DEA should clarify its interpretation of 'general office use,' 'order' and 'prescription'" and that the agency should "explain how the difference, if any, between the practices of human and veterinary medicine might affect its analysis."

Malmberg added, "This ruling tells us that we were correct in making arguments that the DEA rejected or ignored. We welcome the opportunity that this ruling now creates to arrive at a clear, sound understanding that works for all concerned. We want nothing more than to work cooperatively with DEA to resolve any issues it may still have with the current state of compounding- pharmacy practice in the veterinary profession."

The court decision is available at

About Wedgewood Pharmacy

Wedgewood Pharmacy is the largest veterinary compounding pharmacy in the United States, serving more than 20,000 prescribers of animal and human compounds. A compounding pharmacy creates customized medications for individual patients in response to a licensed practitioner's prescription.

Background: About Compounding

Because every patient is different and has different needs, customized, compounded medications are a vital part of quality medical care.

The basis of the profession of pharmacy has always been the "triad," the patient-physician-pharmacist relationship. Compounding is extremely important to the veterinary community, which often requires more flavors, dosages and strengths than commercially available medications supply. Through this relationship, patient needs are determined by a doctor, who chooses a treatment regimen that may include a compounded medication. Physicians and veterinarians often prescribe compounded medications for reasons that include (but are not limited to) the following situations:

-- When needed medications are discontinued by or generally unavailable

from pharmaceutical companies, often because the medications are no

longer profitable to manufacture;

-- When the patient is allergic to certain preservatives, dyes or binders

in available off-the shelf medications;

-- When treatment requires tailored dosage strengths for patients with

unique needs (for example, an infant);

-- When a pharmacist can combine several medications the patient is taking

to increase compliance;

-- When the patient cannot ingest the medication in its commercially

available form and a pharmacist can prepare the medication in cream,

liquid or other form that the patient can easily take; and

-- When medications require flavor additives to make them more palatable

for some patients, most often children and pets.

For additional information, visit the International Academy of Compounding Pharmacists' Web site at and

Marcy Kelly David Kirk, APR, Fellow PRSA

Vice President, Marketing 610.422.0048


SOURCE Wedgewood Pharmacy
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement
2. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
3. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
6. Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam
7. Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research
8. Filing for Reconsideration/Press Conference ACUNA v. TURKISH, Historic Informed Consent Abortion Case to the New Jersey Supreme Court
9. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
10. NBME Appeals Massachusetts Judges Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam
11. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology: